Drug Patent Cliffs was among the worst performers today. It delivered +0.01% to close at 606.575. During the last week it delivered -8.59% and saw a maximum drawdown of -8.6% before bouncing back.
~DRUGGENERICS is currently in a bearish trend. Over the last three months 2 bearish signals have generated a profit of +20.35% for investors.
~DRUGGENERICS has been underperforming the SP500 index in recent time. It showed significant underperformance (compared to the SP500 index) from 20 Jan, 2016 to 10 May, 2018. Over the last 2 years 11 months and 14 days, ~DRUGGENERICS underperformed the SP500 index on 51% days.
During the last three months ~DRUGGENERICS was mostly loss making and delivered on average -0.45% per day. It's best return during this period (of +3.95%) was on Thursday, 1 Nov, 2018. While it's worst loss in the same period (of -4.71%) was on Wednesday, 24 Oct, 2018. The longest stort-term trend during this period was 5 losing days, which started on 21 Sep, 2018 and ended on 27 Sep, 2018. This bearish trend lost -3.03% of investor capital.
The last 12 months saw ~DRUGGENERICS's investors making profits in 5 months and incurring losses in 7 months. ~DRUGGENERICS was less consistent in delivering monthly returs than SP500 index. ~DRUGGENERICS was also a more risky investment than SP500 index as it's worst month in the last year, Dec 2018, returned -15.76% compared to -7.75% returned by SP500 index in Dec 2018. ~DRUGGENERICS had a shorter streak of profitable months than SP500 index. It only went up in 5 straight months during the last year. It is interesting to note that both ~DRUGGENERICS and SP500 index significantly outperform during months when quarterly/annual results are announced.
"I am particularly pleased to see that the Bendheim Center for Finance is thriving.
~DRUGGENERICS is currently seeing overall increase in volatility. In comparison, the SP500 index is seeing increase in volatility. During the last three months, there was a significant surge in ~DRUGGENERICS's volatility from 19 Sep, 2018 to 14 Dec, 2018. While there was a significant surge in the SP500 index's volatility from 19 Sep, 2018 to 29 Oct, 2018.
Advanced/professional short-term investors should note that ~DRUGGENERICS has positive skewness in it's return distribution. This indicates that investors can expect ~DRUGGENERICS to make attempts to recover from drawdowns quickly. Which makes ~DRUGGENERICS a good candidate for momentum based trading on short-term bullish trends or counter-trends.
~DRUGGENERICS has more chance of extreme outcomes than the SP500 index. Therefore, ~DRUGGENERICS must receive a lower allocation than SP500 in your portfolio. SP500 index usually has shorter drawdown period than ~DRUGGENERICS.
Based on your interest in ~DRUGGENERICS you may find it interesting to know that OPNT and ICPT are highly volatile and therefore risky. Investors should consider limiting their exposure to these instruments (because of their volatile nature).
... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.
All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.
We want to empower investors with all the tools and analysis required by them to make a rational investment decision.If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute